表紙
市場調查報告書
商品編碼
1044144

全球液體活檢市場:2021

The World Liquid Biopsy Market 2021

出版日期: | 出版商: Kalorama Information | 英文 228 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

液體活檢檢測有望在臨床腫瘤學方面有很多應用。

本報告探討了全球液體活檢市場,並通過分析、應用、癌症類型、地區和進入市場的公司概況提供了市場概況以及趨勢。

目錄

第 1 章執行摘要

  • 簡介
  • 液體活檢技術
  • 產業結構
  • 液體活檢市場收入和預測

第2章液體活檢技術

  • 簡介
  • 目前主要的液體活檢技術

第3章循環腫瘤DNA(CTDNA)液體活檢

  • 簡介
  • CTDNA在液體活檢中的優勢和局限性
  • 目前基於 CTDNA 的液體活檢測試
  • 基於 CTDNA 的液體活檢測試正在開發中

第4章循環腫瘤細胞(CTCS)液體活檢

  • 簡介
  • 開發基於 CTC 的液體活檢測試面臨的挑戰
  • 基於CTC的液體活檢測試
  • 正在開發基於 CTC 的液體活檢測試

第5章細胞外囊泡和其他液體活檢

  • 簡介
  • 細胞外囊泡/其他基於分析物的液體活檢測試
  • 正在開發的細胞外囊泡/其他基於分析物的液體活檢測試

第6章多分析物液體活檢試驗

  • 簡介
  • 基於多分析物的液體活檢測試
  • 正在開發的基於多分析物的液體活檢測試

第 7 章液體活檢試驗僅用於研究目的

  • 簡介
  • 液體活檢測試僅用於研究目的

第8章液體活檢行業分析

  • 簡介
  • 衝突結構
  • 競爭因素
  • 重要的市場趨勢
  • 個性化醫療
  • 延長世界預期壽命
  • 新型液體活檢產品
  • 改進了基因檢測的可訪問性
  • 監管障礙
  • 第三方付款人覆蓋範圍
  • 經過驗證的臨床實用性
  • 特定癌症的發病率
  • 液體活檢市場的競爭對手

第9章液體活檢市場

  • 市場概況
  • 市場預測

第 10 章市場分析物

  • 循環腫瘤DNA
  • 循環腫瘤細胞
  • 細胞外囊泡和其他分析人員
  • 多分析物

第 11 章按用途市場

  • 治療指導和監測
  • 診斷/篩查
  • 疾病預後

第 12 章按癌症類型劃分的市場

  • 乳腺癌
  • 大腸癌
  • 肺癌
  • 卵巢癌
  • 前列腺癌
  • 其他

第13章液體活檢公司簡介

  • 液體活檢市場10大公司
    • ADAPTIVE BIOTECHNOLOGIES
    • AGENA BIOSCIENCE, INC
    • ANGLE, PLC
    • ASPIRA WOMEN'S HEALTH
    • BIOCARTIS GROUP NV
    • BIOCEPT, INC
    • BIODESIX
    • CELLMAX LIFE
    • CIRCULOGENE
    • DIACARTA, INC
    • EPIC SCIENCES
    • EPIGENOMICS AG
    • EXACT SCIENCES
    • EXOSOME DIAGNOSTICS, INC
    • FOUNDATION MEDICINE, INC(ROCHE)
    • FREENOME, INC
    • GILUPI GMBH
    • GRAIL
    • GUARDANT HEALTH, INC
    • HOLOGIC
    • LUNGLIFE AI
    • MDXHEALTH
    • MENARINI-SILICON BIOSYSTEMS, SPA
    • MYRIAD GENETICS, INC
    • NATERA, INC.
    • NEOGENOMICS LABORATORIES, INC.
    • ONCOCYTE CORPORATION
    • ONCODNA SA
    • ONCIMMUNE
    • PERSONAL GENOME DIAGNOSTICS
    • PREDICINEQ2 SOLUTIONSQIAGEN N.V.
    • Cell-free DNA Technologies
    • CTC Technologies
    • Exosome and miRNA Technologies
    • RESOLUTION BIOSCIENCES(AGILENT)
    • ROCHEDIAGNOSTICS
    • STAGEZERO LIFE SCIENCES
    • SYSMEX-INOSTICS, INC.
    • TEMPUS
    • VERACYTE
    • VOLITIONRX
目錄
Product Code: 21-021b

This report, “The World Liquid Biopsy Market, 2021 ”, from Kalorama Information, contains up-to-date information and useful data points for business planning:

  • Research vs. Clinical Liquid Biopsy
  • The Market for Liquid Biopsy by Region
  • The Market for Liquid Biopsy Market by Type of Analyte
  • The Market for CTC-based Liquid Biopsy
  • The Market for ctDNA-based Liquid Biopsy
  • The Market for EV and Exosome-based Liquid Biopsy
  • The Market for Multi-Analyte-based Liquid Biopsy
  • The Market for Other Liquid Biopsy
  • Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
  • Selected ctDNA-based Liquid Biopsy Tests in Development
  • Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
  • Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

  • Early detection and diagnosis / screening
  • Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
  • Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
  • Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
  • Prognosis of disease

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • INTRODUCTION
  • LIQUID BIOPSY TECHNOLOGIES
  • INDUSTRY STRUCTURE
  • LIQUID BIOPSY MARKET REVENUES AND FORECAST
    • Figure 1-1: Global Liquid Biopsy Market by Geographic Region, 2021 (%)
    • Table 1-1: Global Liquid Biopsy Market Forecast, by Region ($ millions), 2021-2026
    • Figure 1-2: Global Liquid Biopsy Market Forecast by Region $ millions), 2021-2026

CHAPTER 2: LIQUID BIOPSY TECHNOLOGIES

  • INTRODUCTION
    • Table 2-1: Comparison of Tissue and Liquid Biopsy
  • CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES
    • Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies

CHAPTER 3: CIRCULATING TUMOR DNA (CTDNA) LIQUID BIOPSY

  • INTRODUCTION
  • ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
  • CURRENT CTDNA-BASED LIQUID BIOPSY TESTS
    • Table 3-1: Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2021
  • Biocartis
  • Biocept
  • Biodesix
  • CellMax Life
  • Circulogene
  • Diacarta
  • Epigenomics
  • Foundation Medicine (Roche)
  • Guardant Health
  • Inivata (Neogenomics)
  • LungLife AI
  • Myriad Genetics
  • NeoGenomics
  • OncoDNA
  • Personal Genomic Diagnostics
  • QIAGEN
  • Resolution Biosciences
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus
  • CTDNA-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development
  • Exact Sciences
  • Freenome
  • GRAIL
  • Neogenomics

CHAPTER 4: CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY

  • INTRODUCTION
  • CHALLENGES IN THE DEVELOPMENT OF CTC-BASED LIQUID BIOPSY TESTS
  • CTC-BASED LIQUID BIOPSY TESTS
    • Table 4-1: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
  • Adaptive Biotechnologies
  • Biocept
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
  • CTC-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2021
  • ANGLE
  • Epic Sciences
  • Liquid Biotech USA

CHAPTER 5: EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY

  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES / OTHER ANALYTES
    • Table 5-1: Selected Market-Available Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2021
  • Aspira Women's Health (formerly Vermillion)
  • Biodesix
  • Exosome Diagnostics
  • Hologic
  • MDxHealth
  • EXTRACELLULAR VESICLE/OTHER ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2021
  • Circulogene
  • OncoCyte
  • Resolution Biosciences
  • VolitionRx

CHAPTER 6: MULTI-ANALYTE LIQUID BIOPSY TESTS

  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON MULTIPLE ANALYTES
    • Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021
  • Biocept
  • Biodesix
  • Foundation Medicine (Roche)
  • LungLife AI
  • NeoGenomics
  • OncoDNA
  • MULTIPLE ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2021
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

CHAPTER 7: LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY

  • INTRODUCTION
  • LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY
    • Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2021
  • Agena Bioscience
  • ANGLE
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • Natera
  • QIAGEN

CHAPTER 8: LIQUID BIOPSY INDUSTRY ANALYSIS

  • INTRODUCTION
  • TIERS OF COMPETITION
    • Table 8-1: Selected Participants in the Liquid Biopsy Market, 2021
  • COMPETITIVE FACTORS
  • SIGNIFICANT MARKET TRENDS
    • Table 8-2: Significant Trends in the Liquid Biopsy Market, 2021
  • Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers
  • COMPETITORS NO LONGER IN THE LIQUID BIOPSY MARKET
    • Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market

CHAPTER 9: LIQUID BIOPSY MARKET

  • MARKET OVERVIEW
    • Figure 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Analyte, 2021 (%)
    • Figure 9-2: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2021 (%)
    • Figure 9-3: Global Liquid Biopsy Market Estimate by Type of Use, (Research Use, Clinical Diagnostics Use) 2018 (%)
  • MARKET FORECAST
    • Table 9-1: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World, World ($ millions), 2021-2026
    • Figure 9-4: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World ( $ millions), 2021-2026

CHAPTER 10: MARKET BY ANALYTE

  • CIRCULATING TUMOR DNA
    • Market Overview
    • Applications
    • Technologies
    • Specimens
    • Revenue Forecast
      • Table 10-1: Global Liquid Biopsy Market for ctDNA ($ millions), 2021-2026
  • CIRCULATING TUMOR CELLS
    • Market Overview
    • Applications
    • Technologies
    • Specimens
    • Revenue Forecast
      • Table 10-2: Global Liquid Biopsy Market for CTCs ($ millions), 2021-2026
  • EXTRACELLULAR VESICLES AND OTHER ANALYTES
    • Market Overview
    • Applications
    • Technologies
    • Specimens
    • Revenue Forecast
      • Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles ($ millions), 2021-2026
  • MULTIPLE ANALYTES
    • Market Overview
    • Revenue Forecast
      • Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2018-2023

CHAPTER 11: MARKET BY APPLICATION

  • THERAPY GUIDANCE AND MONITORING
    • Market Overview
    • Revenue Forecast
      • Table 11-1: Liquid Therapy for Therapy Guidance ($ millions), 2021-2026
  • DIAGNOSIS/SCREENING
    • Market Overview
    • Revenue Forecast
      • Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening ($ millions), 2021-2026
  • DISEASE PROGNOSIS
    • Market Overview
    • Revenue Forecast
      • Table 11-3: Global Liquid Biopsy Market for Disease Prognosis ($ millions), 2021-2026

CHAPTER 12: MARKET BY CANCER TYPE

  • BREAST CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-1: Global Liquid Biopsy Market for Breast Cancer ($ millions), 2021-2026
  • COLORECTAL CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer ($ millions), 2021-2026
  • LUNG CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-3: Global Liquid Biopsy Market for Lung Cancer ($ millions), 2021-2026
  • OVARIAN CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer ($ millions), 2021-2026
  • PROSTATE CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-5: Global Liquid Biopsy Market for Prostate Cancer ($ millions), 2021-2026
  • OTHER CANCERS
    • Market Overview
    • Revenue Forecast
      • Table 12-6: Global Liquid Biopsy Market for Other Cancers ($ millions), 2021-2026

Notes: *Including bladder, gastrointestinal, pancreatic, renal, melanoma and hematological malignancies.

  • PAN-CANCER TESTS
    • Market Overview
    • Revenue Forecast
      • Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing ($ millions), 2021-2026

CHAPTER 13: LIQUID BIOPSY COMPANY PROFILES

  • TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET
    • Table 13-1
  • Top Ten Companies in the Liquid Biopsy Market
    • ADAPTIVE BIOTECHNOLOGIES
    • AGENA BIOSCIENCE, INC.
    • ANGLE, PLC
    • ASPIRA WOMEN'S HEALTH
    • BIOCARTIS GROUP NV
    • BIOCEPT, INC.
    • BIODESIX
    • CELLMAX LIFE
    • CIRCULOGENE
    • DIACARTA, INC.
    • EPIC SCIENCES
    • EPIGENOMICS AG
    • EXACT SCIENCES
    • EXOSOME DIAGNOSTICS, INC.
    • FOUNDATION MEDICINE, INC. (ROCHE)
    • FREENOME, INC.
    • GILUPI GMBH
    • GRAIL (ILLUMINA)
    • GUARDANT HEALTH, INC.
    • HOLOGIC
    • LUNGLIFE AI (FORMERLY CYNVENIO BIOSYSTEMS)
    • MDXHEALTH
    • MENARINI-SILICON BIOSYSTEMS, SPA
    • MYRIAD GENETICS, INC.
    • NATERA, INC.
    • NEOGENOMICS LABORATORIES, INC.
    • ONCOCYTE CORPORATION
    • ONCODNA S.A.
    • ONCIMMUNE
    • PERSONAL GENOME DIAGNOSTICS
    • PREDICINEQ2 SOLUTIONSQIAGEN N.V.
    • Cell-free DNA Technologies
    • CTC Technologies
    • Exosome and miRNA Technologies
    • RESOLUTION BIOSCIENCES (AGILENT)
    • ROCHE DIAGNOSTICS
    • STAGEZERO LIFE SCIENCES
    • SYSMEX-INOSTICS, INC.
    • TEMPUS
    • VERACYTE
    • VOLITIONRX